To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 15 01 2021
accepted: 15 03 2021
entrez: 26 4 2021
pubmed: 27 4 2021
medline: 5 5 2021
Statut: epublish

Résumé

This study discusses substantive advances in T cell proliferation analysis, with the aim to provoke a re-evaluation of the generally-held view that Ki-67 is a reliable proliferation marker

Identifiants

pubmed: 33897702
doi: 10.3389/fimmu.2021.653974
pmc: PMC8062736
doi:

Substances chimiques

COVID-19 Vaccines 0
Ki-67 Antigen 0
MKI67 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

653974

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2021 Di Rosa, Cossarizza and Hayday.

Déclaration de conflit d'intérêts

AH is a board member and equity holder in ImmunoQure, AG., and Gamma Delta Therapeutics, and is an equity holder in Adaptate Biotherapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Semin Cell Dev Biol. 2020 Nov;107:28-35
pubmed: 32334991
Elife. 2017 Mar 10;6:
pubmed: 28282024
Nat Immunol. 2019 Mar;20(3):301-312
pubmed: 30664737
J Immunol. 1984 Oct;133(4):1710-5
pubmed: 6206131
Elife. 2019 Nov 19;8:
pubmed: 31742553
Cell Rep. 2020 Nov 17;33(7):108376
pubmed: 33207189
Cell Rep. 2018 Jul 31;24(5):1105-1112.e5
pubmed: 30067968
Bioanalysis. 2016 Dec;8(23):2399-2413
pubmed: 27807982
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Genes Dev. 2004 Nov 15;18(22):2747-63
pubmed: 15545632
J Immunol. 2013 Apr 15;190(8):3985-93
pubmed: 23475214
Nature. 2020 Nov;587(7833):285-290
pubmed: 32879492
Elife. 2016 Mar 07;5:e13722
pubmed: 26949251
Scand J Immunol. 2019 Feb;89(2):e12735
pubmed: 30488973
J Clin Pathol. 2002 Jun;55(6):467-71
pubmed: 12037032
Cytometry A. 2013 Feb;83(2):173-6
pubmed: 23281028
Methods Mol Biol. 2016;1516:91-99
pubmed: 27256436
J Autoimmun. 2020 Aug;112:102466
pubmed: 32414606
Cancer Cell. 2021 Feb 8;39(2):257-275.e6
pubmed: 33476581
Genes Cells. 2016 Oct;21(10):1113-1124
pubmed: 27610954
J Cell Physiol. 2006 Mar;206(3):624-35
pubmed: 16206250
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597
Elife. 2014 May 27;3:e01641
pubmed: 24867636

Auteurs

Francesca Di Rosa (F)

Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), Rome, Italy.

Andrea Cossarizza (A)

Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
National Institute for Cardiovascular Research, Bologna, Italy.

Adrian C Hayday (AC)

Immunosurveillance Laboratory, The Francis Crick Institute, London, United Kingdom.
Peter Gorer Department of Immunobiology, King's College London, London, United Kingdom.
National Institute for Health Research (NIHR) Biomedical Research Center (BRC), Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH